A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
Completed
Incyte Corporation
Phase 2
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in
patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy
parameters of itacitinib.
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
Completed
Incyte Corporation
Phase 2
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will
evaluate safety and efficacy parameters of itacitinib (INCB039110).
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Completed
Incyte Corporation
Phase 1/Phase 2
Test the hypothesis that itacitinib (INCB039110) can be administered safely in combination
with gemcitabine and nab-paclitaxel in subjects with advanced or metastatic cancer.
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Active, not recruiting
Incyte Corporation
Phase 1
The study will be conducted in three parts. Part 1 is a dose escalation phase to determine
the maximum tolerated dose (MTD) of INCB040093, a PI3Kδ inhibitor, or a tolerated,
pharmacologically active dose; Part 2 will evaluate the combination of INCB040093 and
itacitinib (INCB039110), a JAK1 inhibitor, to determine the MTD of the combination or a
tolerated dose that produces substantial pharmacologic inhibition of both targets; Part 3
will further evaluate the chosen doses of INCB040093 alone and in combination with itacitinib
(INCB039110) in subjects with relapsed/refractory B-cell malignancies.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
